GASTROGRAFIN ® Diatrizoate Meglumine and Diatrizoate Sodium Solution USP

Manufacturer
Bracco Diagnostics Inc | E-Z-EM Canada Inc | Justesa Imagen, S.A.U | Merck SL
Effective date
2021-10-04
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-05-31 20:38:03

Label at a glance#

ProductGastrografin
Active ingredientdiatrizoate meglumine, diatrizoate sodium
Label structure13 sections

Indications and uses

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Gastrografin may also be used as an adju...

Dosage and administration

This medium is not to be used for the preparation of solutions for parenteral administration. Oral or rectal administration only. Discard any unused portion after procedure. The routine preparatory measures employed for barium studies are also appropriate for this agent. For pediatric and severely cachectic patients the maintenance of an intravenous fluid line may be advisable. Oral Administration: Adult oral dosa...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is a palatable lemon-flavored water-soluble iodinated radiopaque contrast medium for oral or rectal administration only. Each mL contains 660 mg diatrizoate meglumine and 100 mg diatrizoate sodium; pH has been adjusted to 6.0 to 7.6 with sodium hydroxide. Each mL contains approximately 4.8 mg (0.21 mEq) sodium and 367 mg organically bound iodine. Inactive ingredients: edetate disodium, flavor, polysorbate 80, purified water, saccharin sodium, simethicone, and sodium citrate.

Diatrizoate meglumine is designated chemically as 1-deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6-triiodo-benzoate (salt); diatrizoate sodium is monosodium 3, 5-diacetamido-2,4,6-triiodobenzoate. Structural formulas:

Gastrografin Structure
Gastrografin Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast with surrounding tissues.

Diagnostic enteral radiopaque agents have few known pharmacological effects. Diatrizoate meglumine and diatrizoate sodium exert a mild laxative effect attributable to their high osmolarity.

Diatrizoate meglumine and diatrizoate sodium are sparingly absorbed from the intact gastrointestinal tract, and therefore permit gastrointestinal opacification and delineation after oral or rectal administration. Oral administration is used for radiographic evaluation of the esophagus, stomach and proximal small intestine. Rectal administration is used for examination of the colon; however, visualization of the distal small bowel is generally unsatisfactory, since the hypertonicity of the medium causes intraluminal diffusion of water with subsequent dilution of the medium. Enough absorption from the gastrointestinal tract to permit incidental visualization of the urinary tract has been reported; this should also be considered when thyroid testing is being contemplated, since iodine-mediated thyrotropic effects may occur (see PRECAUTIONS).

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous.

Gastrografin may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Do not administer to patients with a known hypersensitivity to Gastrografin or any of its components.

WARNINGS

WARNINGS SECTION

Dehydration: Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine. A 1 in 4.6 (1:4.6) dilution of Gastrografin yields an approximately isotonic 16.5 percent diatrizoate salts solution; less dilute solutions are hypertonic and may lead to intraluminal movement of fluid with resulting hypovolemia. In young or debilitated children and in elderly cachectic persons, the loss of plasma fluid may be sufficient to cause a shock-like state. If Gastrografin is used in infants and children (under 10 kg) or in dehydrated or debilitated patients, the solution must be prepared using the specific dilutions described in DOSAGE AND ADMINISTRATION. In debilitated patients and in patients with electrolyte imbalances, postprocedural monitoring of hydration, serum osmolarity, electrolytes and clinical status is essential. In pediatric or severely debilitated patients, the maintenance of an open intravenous fluid line for rehydration may be advisable should hypotension or shock supervene. Electrolyte disturbances must be corrected prior to the administration of any hypertonic Gastrografin solutions.

Aspiration: Aspiration of Gastrografin into the trachea and airways may result in serious pulmonary complications including, pulmonary edema, pneumonitis or death Bronchial entry of any orally administered contrast medium causes a copious osmotic effusion. Therefore, avoid use of Gastrografin in patients with esophagotracheal fistula and minimize risks for pulmonary aspiration in all patients. If Gastrografin is given by nasogastric tube, the position of the tube in the stomach must be verified before administration.

Anaphylactic reactions: Anaphylactic reactions, including fatalities, have been reported with the use of Gastrografin. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). Medical personnel trained in the treatment of anaphylactic reactions and the necessary drugs and medical equipment should always be readily available when Gastrografin is used.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of administration, as well as for treatment of reaction to the contrast medium (see ADVERSE REACTIONS, and PRECAUTIONS, Information for the Patient).

Rectal administration of undiluted Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) in any patient, particularly with large doses and/or in those with overdistention, has been reported to be associated with mucosal irritation.

Cases of hyperthyroidism have been reported with the use of oral contrast media. Some of these patients reportedly had multinodular goiters which may have been responsible for the increased hormone synthesis in response to excess iodine. Administration of an intravascular iodinated radiopaque diagnostic agent to a hyperthyroid patient precipitated thyroid storm; a similar situation could follow administration of oral preparations of iodides. Therefore, caution should be exercised when administering enteral gastrointestinal radiopaque agents to hyperthyroid and euthyroid goiterous patients.

Consideration should be given to the potential for precipitation of water-soluble contrast agents under conditions that may promote hyperacidity (i.e., fasting, emotional upset, or stress). Harmful effects directly attributable to precipitate formation have not been reported. However, the possibility of interpreting the precipitate radiologically as an anatomical abnormality (i.e., ulceration of the stomach or small intestine) or injury, should be kept in mind.

Information for the Patient

INFORMATION FOR PATIENTS SECTION

Patients should receive the following information and instructions:

  1. This drug has been prescribed to perform an x-ray of the gastrointestinal tract.
  2. Inform the physician if pregnant or if allergic to iodine, any foods, or x-ray materials.
  3. The iodine in diatrizoate salts may interfere with some thyroid tests if these are needed in the future. Inform the attending physician at that time about this gastrointestinal study.
  4. This drug may cause abdominal cramping, nausea, vomiting, diarrhea, skin rashes, itching, heartburn, dizziness, or headache in some patients, but most reactions are mild and pass quickly.

Drug/Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

Thyroid Function Tests

SPL UNCLASSIFIED SECTION

The results of protein bound iodine (PBI) and radioactive iodine uptake studies, which depend on iodine estimations, will not accurately reflect thyroid function for six months, and possibly as long as one year, following the administration of diagnostic enteral radiopaque media.

Thyroid function tests, if indicated, generally should be performed prior to the administration of any iodinated agent. However, thyroid function can be evaluated after use of these agents by using T3 resin uptake and total or free thyroxine (T4) assays which are not dependent on iodine estimations.

Pancreatic Tests

SPL UNCLASSIFIED SECTION

Small quantities of contrast medium in the intestinal tract may cause false low trypsin values when determined spectrophotometrically. Therefore, duodenal instillation should not precede pancreatic function tests involving spectrophotometric trypsin assays.

Any test which might be affected by contrast media should be performed prior to administration of the contrast medium.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate carcinogenic or mutagenic potential, or possible impairment of fertility in males or females.

Pregnancy

PREGNANCY SECTION

When administered intravenously, diatrizoate salts cross the placenta and are evenly distributed in fetal tissues.

No teratogenic effects attributable to diatrizoate meglumine or diatrizoate sodium have been observed in teratology studies performed in animals. There are, however, no adequate and well-controlled studies in pregnant women. Because small amounts of these agents may be absorbed, and animal teratology studies are not always predictive of human response, these agents should be used during pregnancy only when clearly needed.

Procedures including radiation involve a certain risk related to the exposure of the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

Diatrizoate meglumine is excreted in breast milk following intravascular administration.

Because small amounts of enteral gastrointestinal radiopaque agents may be absorbed following oral or rectal administration, caution should be exercised when they are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

See WARNINGS, and PRECAUTIONS, General.

Local injury to the colonic mucosa, particularly in the presence of underlying disease which interferes with intestinal viability, has been reported in cases where recommended doses and dilutions (see DOSAGE AND ADMINISTRATION) were not used; when extemporaneous dosage is elected, the polysorbate 80 level in the dose may be a contributing factor to injury.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Most adverse reactions to enteral diagnostic radiopaque agents are mild and transitory. Nausea, vomiting and/or diarrhea, urticaria with erythema, hypoxia, acute dyspnea, tachyarrhythmia, and anaphylaxis have occurred following ingestion of the contrast medium, particularly when high concentrations of large volumes of solution are administered. Severe changes in serum osmolarity and electrolyte concentrations may produce shock-like states (see WARNINGS). It should be kept in mind that serious or anaphylactoid reactions that may occur with intravascular administration of radiopaque contrast agents are theoretically possible following administration by other routes.

OVERDOSAGE

OVERDOSAGE SECTION

See WARNINGS regarding potential hypovolemia, hypotension, or shock. The maintenance of an open intravenous fluid line for rehydration may be advisable. See DOSAGE AND ADMINISTRATION for appropriate doses and dilutions. Treatment of an overdose should be directed toward the support of all vital functions, and prompt institution of symptomatic therapy.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

General

SPL UNCLASSIFIED SECTION

This medium is not to be used for the preparation of solutions for parenteral administration. Oral or rectal administration only. Discard any unused portion after procedure.

The routine preparatory measures employed for barium studies are also appropriate for this agent.

For pediatric and severely cachectic patients the maintenance of an intravenous fluid line may be advisable.

Radiographic Examination of Segments of the Gastrointestinal Tract

SPL UNCLASSIFIED SECTION

Oral Administration: Adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For infants and children less than 5 years of age, 30 mL (11 g iodine) are usually adequate; for children 5 to 10 years of age, the suggested dose is 60 mL (22 g iodine). These pediatric doses may be diluted 1:1, if desired, with water, carbonated beverage, milk, or mineral oil. When used in infants, the solution may be given in a nursing bottle. Pediatric doses may also be used in dehydrated and/or debilitated adult patients. A 1:1 dilution is also recommended when the contrast medium is used in elderly cachectic individuals.

For very young (under 10 kg) and debilitated children the dose should be diluted: 1 part Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution) in 3 parts water is recommended.

For Enemas or Enterostomy Instillations: Gastrografin should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. For children under 5 years of age, a 1:5 dilution in tap water is suggested; for children over 5 years of age, 90 mL (33 g iodine) in 500 mL of tap water is a suitable dilution.

Tomography (Body Imaging)

SPL UNCLASSIFIED SECTION

A usual adult dose is 240 mL of a dilute Gastrografin solution prepared by diluting 25 mL (9.17 g iodine) to one liter with tap water. Less dilute solutions [up to 77 mL (28.26 g iodine) diluted to one liter with tap water] may be used when indicated. The dose is administered orally about 15 to 30 minutes prior to imaging in order to permit the contrast medium to reach the pelvic loops.

HOW SUPPLIED

HOW SUPPLIED SECTION

Gastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP) is available in packages of:
Twenty-four 30 mL single dose bottles (NDC 0270-0445-35).
Twelve 120 mL single dose bottles (NDC 0270-0445-40).

Storage

STORAGE AND HANDLING SECTION

Protect from light. Store at 20-25°C (68-77°F) [See USP]; avoid excessive heat.

SPL UNCLASSIFIED SECTION

Manufactured by E-Z-EM Canada Inc,
Anjou, Quebec H1J2Z4, Canada
For Bracco Diagnostics Inc.
Monroe Township, NJ 08831

Rev. August 2019
CLE7903

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Gastrografin® 120 mL Label
NDC 0270-0445-40

Gastrografin label 120ml
Gastrografin label 120ml

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Gastrografin® 12 x 120 mL Bottles Label
NDC 0270–0445–40

Gastrografin label 12x120
Gastrografin label 12x120

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DIATRIZOIC ACID Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a8f1679b-19b1-407c-9ee3-d33055bee6fcProduct name220250731
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0270-0445-35Gastrografin24 in 1 BOXLIQUID248
0270-0445-35Gastrografin30 mL in 1 BOTTLELIQUID308
0270-0445-40Gastrografin120 mL in 1 BOTTLELIQUID1208
0270-0445-40Gastrografin12 in 1 BOXLIQUID128

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0270-0445GASTROGRAFIN (DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM) LIQUID [BRACCO DIAGNOSTICS INC]8Current NDC, Legacy NDC, 4 package rows20211013_8c2340e4-2b42-45dc-8fac-9960e8172547.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0270-0445-35ML - Milliliter0270-0445dbe2ba48-7d1c-44da-b913-5e6d22c4d52912012-07-24
0270-0445-40ML - Milliliter0270-0445cb902fc1-6290-43ed-9204-622bef0497e912012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
diatrizoate meglumineACTIVE INGREDIENT3X9MR4N98U4
diatrizoate sodiumACTIVE INGREDIENTV5403H8VG74
DIATRIZOIC ACIDACTIVE MOIETY5UVC90J1LK4
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K4
SACCHARIN SODIUM DIHYDRATEINACTIVE INGREDIENTSB8ZUX40TY4
SODIUM CITRATEINACTIVE INGREDIENT1Q73Q2JULR4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0270-04450270-0445-35, 0270-0445-40

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 6 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SACCHARIN SODIUM DIHYDRATESACCHARIN SODIUMSB8ZUX40TYLIQUID / ORAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SACCHARIN SODIUM DIHYDRATESACCHARIN SODIUMSB8ZUX40TYLIQUID / ORAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KLIQUID / ORAL0.5 mg/1mlExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KLIQUID / ORAL0.5 mg/1mlExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KLIQUID / ORAL0.5 mg/1mlExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SACCHARIN SODIUM DIHYDRATESACCHARIN SODIUMSB8ZUX40TYLIQUID / ORAL3 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N011245-003GASTROGRAFINDIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N011245-003AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N011245-003GASTROGRAFIN66%;10%SOLUTION / ORAL, RECTALAARLD, RS, Approved before 19823bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N011245-003AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09N011245-003AA1c2088c7a36db…
2026-09-14 22:38:342026-08N011245-003AA184e616aacf4f…
2026-08-18 06:07:402026-07N011245-003AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N011245-003AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011245-003AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08N011245-003AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011245-003AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011245-003AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011245-003AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011245-003AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011245-003AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N011245-003AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N011245-003AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N011245-003AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N011245-003AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N011245-003AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N011245-003AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N011245-003AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N011245-003AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N011245-003AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N011245-003AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N011245-003AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N011245-003AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N011245-003AA187673890dc5c…
2021-03-12 10:30 UTC2021-03N011245-003AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N011245-003AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N011245-003AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N011245-003AA13f01610625f2…
2019-09-15 20:21 UTC2019-09N011245-003AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07N011245-003AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N011245-003AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N011245-003AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N011245-003AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N011245-003AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N011245-003AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N011245-003AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N011245-003AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05N011245-003AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01N011245-003AA13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
GastrografinDIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUMBracco Diagnostics Inc8c2340e4-2b42-45dc-8fac-9960e81725472021-10-04Warnings, Adverse reactionsExact identifier
ndc (package): 0270-0445-40
ndc (package): 0270-0445-35
ndc (product): 0270-0445
ndc11 (package): 00270044535
ndc11 (package): 00270044540
spl id: 7c17ff73-033f-4c13-b31d-3f84a9f88768
spl set id: 8c2340e4-2b42-45dc-8fac-9960e8172547

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.